Search

Your search keyword '"PISCAGLIA, FABIO"' showing total 1,384 results

Search Constraints

Start Over You searched for: Author "PISCAGLIA, FABIO" Remove constraint Author: "PISCAGLIA, FABIO"
1,384 results on '"PISCAGLIA, FABIO"'

Search Results

2. Adverse Events as Potential Predictive Factors of Activity in Patients with Advanced HCC Treated with Atezolizumab Plus Bevacizumab

5. Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib

8. Safety and Efficacy of Lenvatinib in Very Old Patients with Unresectable Hepatocellular Carcinoma

9. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients

10. Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study

12. MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma

14. Multidisciplinary treatment of hepatocellular carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part II – Non-surgical treatments

15. A meta-analysis and real-world cohort study on the sex-related differences in efficacy and safety of immunotherapy for hepatocellular carcinoma

16. Multidisciplinary Treatment of Hepatocellular Carcinoma in 2023: Italian practice Treatment Guidelines of the Italian Association for the Study of the Liver (AISF), Italian Association of Medical Oncology (AIOM), Italian Association of Hepato-Bilio-Pancreatic Surgery (AICEP), Italian Association of Hospital Gastroenterologists (AIGO), Italian Association of Radiology and Clinical Oncology (AIRO), Italian Society of Pathological Anatomy and Diagnostic Cytology (SIAPeC-IAP), Italian Society of Surgery (SIC), Italian Society of Gastroenterology (SIGE), Italian Society of Medical and Interventional Radiology (SIRM), Italian Organ Transplant Society (SITO), and Association of Patients with Hepatitis and Liver Disease (EpaC) – Part I – Surgical treatments

19. Pharmacodynamic Biomarkers Predictive of Survival Benefit with Lenvatinib in Unresectable Hepatocellular Carcinoma: From the Phase III REFLECT StudyBiomarker Analysis Following Lenvatinib in Unresectable HCC

20. Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?

21. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

22. Artificial Intelligence and liver: Opportunities and barriers

23. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis

24. Landscape of alcohol-related hepatocellular carcinoma in the last 15 years highlights the need to expand surveillance programs

25. Personalised management of patients with hepatocellular carcinoma: a multiparametric therapeutic hierarchy concept

26. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis

27. Trends in chronic hepatitis B virus infection in Italy over a 10-year period: Clues from the nationwide PITER and MASTER cohorts toward elimination

28. Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

29. SAT-068 Accuracy of spleen stiffness measurement for the diagnosis of high-risk esophageal varices in patients with advanced chronic liver disease: a systematic review and individual patient data meta-analysis

31. THU-472-YI Sorafenib as a second-line treatment after failure of Atezolizumab/Bevacizumab

32. WED-232-YI Diagnostic accuracy of two-dimensional shear wave elastography (2D-SWE) for non-invasive assessment of liver fibrosis in biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD). Systematic-review and multi-level random effects model meta-analysis

33. THU-471-YI From randomised clinical trials to clinical practice: a systematic reviewand meta-analysis of real-word data on atezolizumab plus bevacizumab for advanced hepatocellular carcinoma

35. SAT-477-YI The impact of etiologyon patterns of progression of advanced HCC

36. TOP-509-YI Validation and improvement of the IMbrave050 criteria for high-risk of HCC-recurrence as an indication to adjuvant treatment: results from a 4-year retrospective competitive-risk study

37. THU-492 Prognostic significance of liver decompensation, liver function and portal hypertension in cirrhotic patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab

38. Ultrasound-Assisted and Ultrasound-Guided Thoracentesis: An Educational Review

39. Liver Imaging Reporting and Data System Contrast-Enhanced US Nonradiation Treatment Response Assessment Version 2024

41. Reader agreement and accuracy of ultrasound features for hepatic steatosis.

42. Characteristics and survival of patients with primary biliary cholangitis and hepatocellular carcinoma

45. RANK–RANKL–OPG Axis in MASLD: Current Evidence Linking Bone and Liver Diseases and Future Perspectives.

46. Circulating microRNAs as biomarkers for stratifying different phases of liver cancer progression and response to therapy.

48. How to perform Contrast-Enhanced Ultrasound (CEUS)

49. Contrast-enhanced ultrasound (CEUS) liver imaging reporting and data system (LI-RADS) 2017 – a review of important differences compared to the CT/MRI system

50. Clinical features and comorbidity pattern of HCV infected migrants compared to native patients in care in Italy: A real-life evaluation of the PITER cohort

Catalog

Books, media, physical & digital resources